4 weeks Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC WainwrightMarketBeat
HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.
XHC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.
X